{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreid644caswraio6rrn5q5gfad47svo3wxj6zp7xhrkf52xwfxfza5i",
    "uri": "at://did:plc:yhmwewfk3g3hhkrw2gf4ypna/app.bsky.feed.post/3mfk53yr2okq2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicsjux4gx4s5tie5sbi3fngsotvllxioi7sql67jbqrpxwrvmzliu"
    },
    "mimeType": "image/png",
    "size": 429427
  },
  "path": "/2026/02/23/worst-case-scenario-novo-nordisk-plunges-after-next-gen-obesity-drug-falls-short-of-lilly-rival/",
  "publishedAt": "2026-02-23T14:25:00.000Z",
  "site": "https://dissentwatch.com",
  "tags": [
    "#Column2"
  ],
  "textContent": "“Worst-Case Scenario”: Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival Shares of Novo Nordisk A/S plummeted again on Monday after the company reported trial results showing its next-generation obesity shot, CagriSema, delivered 20.2% weight loss at 84 weeks, compared to 23.6% for Eli Lilly & Co.’s tirzepatide (Zepbound). Bloomberg Intelligence analyst […]",
  "title": "“Worst-Case Scenario”: Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival"
}